Literature DB >> 9892092

Analysis of the p21 gene in gliomas.

Y J Li1, K Hoang-Xuan, X P Zhou, M Sanson, K Mokhtari, T Faillot, P Cornu, M Poisson, G Thomas, R Hamelin.   

Abstract

The p21 gene encodes a cyclin dependent kinase inhibitor protein (p21) which has a tumor suppressive activity in a variety of tumor cell lines. Since, the p21 gene is up-regulated by the p53 tumor suppressor gene, which is frequently mutated in gliomas, acting therefore in the same control pathway, it constitutes a good candidate gene to be also inactivated in these tumors. To test this hypothesis, DNAs from 81 gliomas (48 glioblastomas, 11 anaplastic astrocytomas, 10 low-grade astrocytomas, 12 oligodendrogliomas and mixed gliomas), were investigated for mutations in the p21 coding sequence by denaturant gradient gel electrophoresis followed by sequencing. All these tumors have been previously screened for p53 mutations. Three different DNA variants were identified on codon 31 (17 cases), 27 (1 case) and 117 (1 case) and shown to be also present in matching constitutional DNA, suggesting they were polymorphisms. None of the tumors demonstrated a somatic mutation. No significant correlation between the presence of a p21 variant and the p53 mutation tumor status was observed. In conclusion, mutation in the p21 gene unlikely contributes to the development of gliomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9892092     DOI: 10.1023/a:1006149021810

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas.

Authors:  M Tenan; F Carrara; S DiDonato; G Finocchiaro
Journal:  Int J Cancer       Date:  1995-07-04       Impact factor: 7.396

2.  Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31.

Authors:  A Marchetti; F Buttitta; S Pellegrini; G Bertacca; A Lori; G Bevilacqua
Journal:  Int J Oncol       Date:  1995-01       Impact factor: 5.650

3.  Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer.

Authors:  X Gao; Y Q Chen; N Wu; D J Grignon; W Sakr; A T Porter; K V Honn
Journal:  Oncogene       Date:  1995-10-05       Impact factor: 9.867

4.  Increased levels of p21WAF1/Cip1 in human brain tumors.

Authors:  J M Jung; J M Bruner; S Ruan; L A Langford; A P Kyritsis; T Kobayashi; V A Levin; W Zhang
Journal:  Oncogene       Date:  1995-11-16       Impact factor: 9.867

5.  Tumor suppression by p21WAF1.

Authors:  Y Q Chen; S C Cipriano; J M Arenkiel; F R Miller
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

6.  Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer.

Authors:  Y J Li; P Laurent-Puig; R J Salmon; G Thomas; R Hamelin
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

7.  Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer.

Authors:  S Mousses; H Ozçelik; P D Lee; D Malkin; S B Bull; I L Andrulis
Journal:  Hum Mol Genet       Date:  1995-06       Impact factor: 6.150

8.  A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma.

Authors:  K Bhatia; S Fan; G Spangler; M Weintraub; P M O'Connor; J G Judde; I Magrath
Journal:  Cancer Res       Date:  1995-04-01       Impact factor: 12.701

9.  The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo.

Authors:  Z Y Yang; N D Perkins; T Ohno; E G Nabel; G J Nabel
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

10.  Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours.

Authors:  J Koopmann; D Maintz; S Schild; J Schramm; D N Louis; O D Wiestler; A von Deimling
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

View more
  5 in total

Review 1.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

2.  Prognostic significance of p53 and p21WAF1/CIP1 immunoreactivity and tumor micronecrosis for recurrence of meningiomas.

Authors:  Y Kamei; M Watanabe; T Nakayama; K Kanamaru; S Waga; T Shiraishi
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

3.  Significant association of PRMT6 hypomethylation with colorectal cancer.

Authors:  Ranran Pan; Hang Yu; Jie Dai; Cong Zhou; Xiuru Ying; Jie Zhong; Jun Zhao; Yihan Zhang; Boyi Wu; Yiyi Mao; Dongping Wu; Jieer Ying; Shiwei Duan
Journal:  J Clin Lab Anal       Date:  2018-06-21       Impact factor: 2.352

4.  Immunohistochemical markers for prognosis of ependymal neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Valery Timirgaz
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

5.  Immunohistochemical markers for prognosis of oligodendroglial neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.